Genprex, Inc. 2022 Form 10-K Summary
Business context and reporting period
Genprex is a clinical-stage gene therapy company with oncology and diabetes programs. Its lead candidate, REQORSA (quaratusugene ozeplasmid), uses the non-viral ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 tumor-suppressor gene. REQORSA is being developed with Tagrisso for NSCLC, Keytruda for NSCLC, and Tecentriq for extensive-stage SCLC. GPX-002 and GPX-003 are preclinical gene therapy candidates for Type 1 and Type 2 diabetes, respectively.
The filing covers the fiscal year ended December 31, 2022, and was filed March 31, 2023. The source text does not provide a separate fourth-quarter income statement; annual results and unaudited quarterly information through the third quarter are presented.
Financial performance, liquidity, and capitalization
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $11.5 million | $9.0 million | Up 28% |
| General and administrative expense | $12.3 million | $11.7 million | Up 5% |
| Total costs and expenses | $23.8 million | $20.7 million | Up 15% |
| Net loss | $23.7 million | $20.7 million | Up 15% |
| Net loss per share | $0.50 | $0.44 | Greater loss per share |
| Net cash used in operating activities | $17.8 million | $14.3 million | Use increased 24% |
| Cash and cash equivalents | $21.0 million | $38.6 million | Down $17.7 million |
| Debt | None | None | No interest expense |
| Accumulated deficit | $102.8 million | $79.1 million | Increased $23.7 million |
Because Genprex has no revenue, gross and operating margins are not meaningful. The company reported $90,098 of interest income and no interest expense in 2022. Management estimated that cash on hand would fund current operations and planned clinical-trial activities into the second quarter of 2024, but stated that additional capital will be required to complete development and commercialization.
Financing activity in 2022 was limited to approximately $4,532 of net proceeds from the ATM program and $1.755 million of gross proceeds from option exercises. The November 2022 ATM permits sales of up to $50 million of common stock; only 3,886 shares had been sold by year-end. The company also had 11.4 million outstanding stock options and 2.1 million outstanding warrants at year-end, creating potential future dilution.
Material changes versus the prior comparable period
- R&D expense increased primarily due to expanded manufacturing and testing, greater use of CROs and other third parties, and increased clinical-trial and preclinical staffing.
- Operating cash use increased as the company advanced the Acclaim-1 and Acclaim-2 trials and expanded its manufacturing programs.
- Cash declined from $38.6 million to $21.0 million, while no comparable large financing occurred in 2022; 2021 included approximately $23.2 million of net proceeds from registered direct offerings.
- Acclaim-1 advanced through three dose cohorts, with the Safety Review Committee approving escalation to 0.12 mg/kg. The filing states that no dose-limiting toxicities occurred at 0.06 mg/kg or 0.09 mg/kg.
- Acclaim-2 was enrolling at 0.06 mg/kg. In March 2023, the protocol was amended to add control-group treatments intended to improve enrollment.
- Genprex filed the Acclaim-3 protocol with the FDA in November 2022 and expected to dose the first patient by the end of the third quarter of 2023.
- The company entered additional University of Pittsburgh license agreements covering diabetes gene therapy technologies and entered a new MD Anderson sponsored research agreement with projected costs of approximately $2.9 million.
- Comparative 2021 financial statements were revised for an immaterial error involving the timing of share-based compensation recognition. The revision increased 2021 net loss by approximately $1.1 million but did not change total assets, total liabilities, or total stockholders’ equity.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects continued operating losses and no product revenue unless and until product candidates are successfully developed, approved, and commercialized.
- Acclaim-1 dose-escalation enrollment was expected to finish shortly after filing, followed by determination of the maximum tolerated dose or recommended Phase 2 dose and dose expansion.
- Acclaim-2 dose-escalation enrollment was expected to be completed by the end of 2023.
- Acclaim-3 was expected to begin dosing by the end of the third quarter of 2023.
- Genprex reported encouraging preclinical Type 1 diabetes data in non-human primates after year-end, including decreased insulin requirements, increased C-peptide, and improved glucose tolerance. These results do not establish clinical efficacy in humans.
- The company completed a March 1, 2023 registered direct offering of 3,809,524 shares and warrants for an additional 3,809,524 shares, generating approximately $3.6 million of net proceeds. The warrants are immediately exercisable for five years at $1.10 per share.
- Management disclosed a material weakness in internal control over financial reporting caused by insufficient segregation of duties. Remediation efforts were underway but had not operated long enough to be considered complete.
- The financial statements contain a going-concern disclosure: Genprex has sustained substantial losses, has no current revenue source, and expects to need additional financing.
- Key risks include clinical-trial failure or delays, patient enrollment challenges, regulatory approval uncertainty, dependence on contract manufacturers and CROs, supply-chain disruption, gene therapy safety concerns, intellectual-property and license risks, dilution from future financings, and potential Nasdaq listing risk.
- Genprex reported no material pending legal proceedings and no outstanding debt at December 31, 2022.
Most important facts for investors to verify
- Cash runway assumptions and the timing, size, and terms of future equity or other financing.
- Enrollment progress, safety findings, dose selection, and efficacy data from Acclaim-1 and Acclaim-2.
- Whether Acclaim-3 begins on schedule and whether the program receives regulatory clearance without additional requirements.
- The company’s ability to remediate the material weakness in internal controls.
- Potential dilution from the $50 million ATM, the March 2023 warrants, outstanding options, and future equity issuances.
- Contract manufacturing capacity, supply availability, product shelf life, and compliance with FDA requirements.
- The terms, milestones, royalties, and termination provisions of the MD Anderson and University of Pittsburgh licenses.
- Whether preclinical diabetes findings translate into safe and effective human clinical treatments.